Advertisement Biogen Idec AVONEX PEN receives CHMP positive opinion - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Biogen Idec AVONEX PEN receives CHMP positive opinion

Biogen Idec has received positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its intramuscular autoinjector, AVONEX PEN for the patients who are suffering from relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

CHMP’s decision was supported by the positive results of a Phase 3b open-label, multicenter study, which investigated the safety and efficacy of AVONEX PEN which demonstarted 89% of success rate in using patients with MS.

Additionally, 94% of patients expressed a preference for AVONEX PEN over the AVONEX Prefilled Syringe.

Over all, the study included patients with MS using AVONEX Prefilled Syringe for at least 12 weeks prior to enrollment.

Efficacy of AVONEX PEN was assessed through objective and subjective assessments of key aspects of patients’ use of AVONEX PEN.

Biogen Idec R&D EVP Douglas Williams said this positive CHMP opinion and authorisation in Canada is a testament to their commitment to not only develop new treatments for the MS community, but their continued drive to further improve patients’ experience with their existing therapies.